<DOC>
	<DOCNO>NCT01987739</DOCNO>
	<brief_summary>This six-way crossover study six single-dose treatment session . The profile acute effect abuse potential measure different almorexant dos compare placebo two dos zolpidem</brief_summary>
	<brief_title>Study Evaluate Relative Abuse Potential Almorexant Recreational Drug Users</brief_title>
	<detailed_description>This prospective , randomize , double-blind , double-dummy , balance , placebo active-controlled , six-way crossover Phase 1 study six single-dose treatment session . The profile acute effect pharmacodynamic abuse potential measure different almorexant dos compare placebo two dos zolpidem .</detailed_description>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>Healthy male female subject 18 55 year age , inclusive . Recreational drug use history CNS depressant use , define least 10 lifetime occasion nonmedical use drug depressant/sedative property ( e.g. , benzodiazepine , barbiturate , gammahydroxybutyric acid ( GHB ) , zopiclone , zolpidem , cannabis , etc . ) , least one instance nonmedical use past year . Body mass index ( BMI ) within range 18 32 kg/m^2 , inclusive , minimum weight 50 kg . Female subject childbearing potential must practice strict sexual abstinence use medically acceptable reliable form birth control failure rate &lt; 1 % per year least 1 month prior Screening ( least 3 month oral contraceptive ) least 1 month last study drug administration . Accepted method contraception include implant , injectables , combine oral hormonal contraceptive , intrauterine device , sexual abstinence , tubal ligation , vasectomized partner . Female subject nonchildbearing potential must amenorrheic least 1 year follow natural menopause hysterectomy and/or bilateral oophorectomy ( determine subject medical history ) . Female subject must negative pregnancy test Screening admission . Must pass Qualification Visit eligibility criterion . Must able speak , read , understand English sufficiently understand nature study , provide write informed consent , allow completion study assessment . Willing able abide study requirement restriction . Give voluntary write informed consent participate study . Received investigational drug clinical trial within 30 day prior Screening Visit . Drug alcohol dependence ( except nicotine caffeine ) past 2 year define Diagnostic Statistical Manual Mental Disorders ( DSMIV ) , include subject ever drug rehabilitation program ( treatment smoke cessation ) . Unwillingness inability abstain recreational drug use require study . Positive urine drug screen admission Qualification Treatment Visit great establish threshold value , except cannabinoids ( THC ; due slow release adipose tissue ) . If THC positive , inclusion discretion investigator designee . Subjects positive urine drug screen reschedule 2times investigator's/designee 's discretion . Positive breath alcohol test Screening admission . Clinically significant abnormality physical examination , medical history , 12lead electrocardiogram ( ECG ) , vital sign , laboratory test , include history presence psychiatric , cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic disease condition , opinion investigator would jeopardize safety subject validity study result . Previous history fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction . Use nonprescription medication , prescription medication , natural health product ( except vitamin mineral supplement , acceptable form birth control , hormone replacement ) within 7 day prior first drug administration Qualification Visit throughout study . Up 1 g per day acetaminophen allow discretion investigator . Concomitant medication know inhibit induce cytochrome P3A4 isoenzyme allow . Treatment drug metabolize cytochrome P2D6 isoenzyme allow . History allergy hypersensitivity study drug , relate drug ( e.g. , benzodiazepine gammaaminobutyric acid relate drug ) excipients ( include lactose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Almorexant</keyword>
	<keyword>Zolpidem</keyword>
</DOC>